NC
JAZZ icon

NinePointTwo Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

NinePointTwo Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$245K Hold
1,992
– – 0.1% 189
2023
Q3 		$257K Buy
+1,992
New +$265K 0.1% 102

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NinePointTwo Capital's JAZZ Position: Q4 2023 in Review

NinePointTwo Capital held its Jazz Pharmaceuticals (JAZZ) position steady in Q4 2023 at 1,992 shares worth $245K. The position accounts for 0.1% of the portfolio, ranked #189.

NinePointTwo Capital first reported a position in JAZZ in Q3 2023 and has held it in 2 quarters since. The position peaked at $257K in Q3 2023. 499 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • NinePointTwo Capital held 1,992 shares of Jazz Pharmaceuticals worth $245K as of Q4 2023.
  • NinePointTwo Capital left its Jazz Pharmaceuticals share count unchanged in Q4 2023.
  • Jazz Pharmaceuticals made up 0.1% of NinePointTwo Capital's portfolio in Q4 2023, its #189 holding.
  • NinePointTwo Capital first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 2 quarters since.
  • NinePointTwo Capital's Jazz Pharmaceuticals position peaked at $257K in Q3 2023.
  • 499 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.